Equities

Shandong Buchang Pharmaceuticals Co Ltd

Shandong Buchang Pharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (CNY)24.28
  • Today's Change-0.18 / -0.74%
  • Shares traded20.33m
  • 1 Year change25.10%
  • Beta1.3208
Data delayed at least 15 minutes, as of Jun 03 2020 08:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Company’s main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.

  • Revenue in CNY (TTM)14.01bn
  • Net income in CNY1.97bn
  • Incorporated2001
  • Employees7.92k
  • Location
    Shandong Buchang Pharmaceuticals Co LtdNo. 369, Zhonghua West RoadHEZE 274009ChinaCHN
  • Phone+86 5 305299167
  • Fax+86 5 305299286
  • Websitehttp://www.buchang.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
603858:SHH since
announced
Transaction
value
Shanghai Hepu Medical Technology Co LtdAnnounced13 Sep 201913 Sep 2019Announced--20.26m
Data delayed at least 15 minutes, as of Jun 03 2020 08:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zhejiang CONBA Pharmaceutical Co., Ltd.6.76bn-339.51m14.43bn9.51k--2.88--2.14-0.1301-0.13012.511.880.64051.544.61710,455.50-2.474.72-4.217.5272.1165.61-3.857.200.91155.190.352660.83-3.5613.57-142.40---8.94--
Zhejiang Medicine Co., Ltd.6.93bn358.25m15.82bn6.42k43.161.96--2.280.37980.37987.148.360.66513.344.921,079,234.002.953.183.844.0138.8132.974.434.981.86--0.101486.862.707.83-5.9715.09-10.3775.54
Tasly Pharmaceutical Group Co Ltd18.38bn848.10m22.34bn9.24k26.241.96--1.220.5630.56312.187.560.75075.312.071,990,227.003.446.905.4112.6129.7735.534.598.401.702.990.425738.635.618.60-35.19-6.05-0.6484--
Shandong Buchang Pharmaceuticals Co Ltd14.01bn1.97bn27.92bn7.92k13.621.94--1.991.801.8012.7912.610.68821.7212.041,768,453.009.7312.1813.0818.0780.7982.8614.1416.440.898425.450.174--4.326.653.058.0126.44--
Jointown Pharmaceutical Group Co Ltd102.01bn1.84bn34.66bn25.80k18.441.90--0.33981.001.0055.389.741.496.414.333,954,377.003.052.6310.057.798.588.342.041.680.95133.150.592862.6414.1919.3639.5122.774.74--
Data as of Jun 03 2020. Currency figures normalised to Shandong Buchang Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.53%Per cent of shares held by top holders
HolderShares% Held
China Southern Asset Management Co., Ltd.as of 31 Dec 20195.82m0.51%
Goldman Sachs Asset Management Internationalas of 29 Feb 20203.95m0.35%
Goldman Sachs Asset Management LPas of 29 Feb 20201.85m0.16%
Robeco Institutional Asset Management BVas of 31 Mar 20201.21m0.11%
GF Fund Management Co., Ltd.as of 31 Dec 20191.16m0.10%
China Asset Management Co., Ltd.as of 31 Dec 2019851.68k0.08%
CPIC Fund Management Co. Ltd.as of 30 Jun 2019815.48k0.07%
BlackRock Advisors (UK) Ltd.as of 06 May 2020667.33k0.06%
The Vanguard Group, Inc.as of 30 Apr 2020658.80k0.06%
Mellon Investments Corp.as of 07 May 2020528.37k0.05%
More ▼
Data from 30 Jun 2019 - 26 May 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.